Search

Displaying results 8081 - 8090 of 10000 in total
  1. Drug

    JNJ-42396302

    go.drugbank.com/drugs/DB12657
    Investigational

    Jnj 42396302 is under investigation in clinical trial NCT01732237 (A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants).

  2. Drug

    OT-730

    go.drugbank.com/drugs/DB16112
    Investigational

    OT-730 is under investigation in clinical trial NCT00753168 (Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma).

  3. Drug

    Izuralimab

    go.drugbank.com/drugs/DB18933
    Investigational

    Izuralimab is under investigation in clinical trial NCT05879185 (A Study of Xmab23104 in People With Sarcoma).

  4. Drug

    CM-4307

    go.drugbank.com/drugs/DB15414
    Investigational

    CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).

  5. Drug

    Acetyldinaline

    go.drugbank.com/drugs/DB16142
    Investigational

    Acetyldinaline is under investigation in clinical trial NCT00005624 (CI-994 in Treating Patients With Advanced Myeloma).

  6. Drug

    GLPG-0492

    go.drugbank.com/drugs/DB12461
    Investigational

    Glpg0492 is under investigation in clinical trial NCT01130818 (First-in-Human Single Ascending Dose of GLPG0492).

  7. Drug

    Ethylhexylglycerin

    go.drugbank.com/drugs/DB14557
    Investigational

    An emollient solvent with antimicrobial activity.

  8. Drug

    Mebhydrolin

    go.drugbank.com/drugs/DB13808
    Investigational

    Mebhydrolin is an antihistamine agent.[A275123]

  9. Drug

    Pidotimod

    go.drugbank.com/drugs/DB11364
    Investigational

    Pidotimod is a synthetic dipeptide with immunomodulatory properties.[A7956]

  10. Drug

    Avadomide

    go.drugbank.com/drugs/DB14857
    Investigational

    Avadomide is under investigation in clinical trial NCT02031419 (Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma).